Satsuma Pharmaceuticals announces three abstracts accepted at AAN meeting

Satsuma Pharmaceuticals announced that three abstracts highlighting STS101 were accepted at the American Academy of Neurology’s, AAN, 75th Annual Meeting. The 2023 meeting will be held in a hybrid virtual and in-person format in Boston, Massachusetts from Saturday, April 22 to Thursday, April 27, 2023. Accepted Abstracts: Title: Interim Analysis of Subject Impression Data for STS101 From the Phase 3 Open-Label ASCEND Study. Summary: This abstract describes results from Satsuma’s Phase 3 ASCEND safety study of STS101. Conclusion: Subject impression data through 12 months suggest that STS101 was perceived very favorably by subjects on multiple measures, including in comparison to their usual migraine medications. Title: Interim Analysis of Long-Term Safety and Tolerability Data of STS101 From the Phase 3 Open-Label ASCEND Study. Summary: This abstract describes results from an interim safety analysis of Satsuma’s Phase 3 ASCEND safety study of STS101. Conclusion: The results of the ASCEND study show that STS101 was well tolerated when used long-term for the acute treatment of migraine attacks. Title: Interim Analysis of STS101 Nasal Safety Data From the Phase 3 Open-Label ASCEND Migraine Study. Summary: This abstract describes results from an interim analysis of Satsuma’s Phase 3 ASCEND safety study of STS101. Conclusion: Nasal safety data from 5,571 treated attacks demonstrate the safety and tolerability of STS101 for the acute treatment of migraine.